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Summary
 
Brain-derived neurotrophic factor (BDNF) has potent effects on neuronal survival and plasticity
during development and after injury. In the nervous system, neurons are considered the major
cellular source of BDNF. We demonstrate here that in addition, activated human T cells, B cells,
and monocytes secrete bioactive BDNF in vitro. Notably, in T helper (Th)1- and Th2-type
CD4
 
1
 
 T cell lines specific for myelin autoantigens such as myelin basic protein or myelin oligo-
dendrocyte glycoprotein, BDNF production is increased upon antigen stimulation. The BDNF
secreted by immune cells is bioactive, as it supports neuronal survival in vitro. Using anti-BDNF
monoclonal antibody and polyclonal antiserum, BDNF immunoreactivity is demonstrable in in-
flammatory infiltrates in the brain of patients with acute disseminated encephalitis and multiple
sclerosis. The results raise the possibility that in the nervous system, inflammatory infiltrates have a
neuroprotective effect, which may limit the success of nonselective immunotherapies.
Key words: neurotrophic factors • multiple sclerosis • autoimmunity • immunosuppressive 
therapy • neurodegeneration
 
B
 
rain-derived neurotrophic factor (BDNF) was cloned
in 1989 (1) as the second member of the neurotrophin
(NT) family which includes nerve growth factor (NGF)
and NT-3, -4/5, -6, and -7 (2). Since then, the important
role of BDNF in regulating the survival and differentiation
of various neuronal populations including sensory neurons,
cerebellar neurons, and spinal motor neurons has been
firmly established (2). Neurons are the major source of
BDNF in the nervous system (2, 3). It is thought that
BDNF and NT4/5 exert their biological function via the
full-length form of 
 
trk
 
B receptor, called gp145
 
trk
 
B (4), ex-
pression of which seems to be restricted to neuronal cell
populations (5).
Several studies have shown that the therapeutic applica-
tion of BDNF prevents neuronal degeneration after axot-
omy and other forms of neuronal injury (6–10). In addi-
tion, beneficial effects of BDNF have been reported in
animal models of neurodegenerative disease (11). Hence,
BDNF is now considered as a potential therapeutic agent
for human neurodegenerative disease, e.g., motor neuron
disease, although clinical trials have not yet been successful
(12). Considering that inflammation is a universal tissue re-
action crucial for defense and repair, we asked whether the
immune cells accumulating in traumatic, degenerative, isch-
emic, infectious, and autoimmune lesions of the nervous
system might provide a natural imported source of BDNF.
 
Materials and Methods
 
Cell Preparations.
 
Ag-specific CD4
 
1
 
 human T cell lines were
isolated as described (13). PBMCs were separated into CD4
 
1
 
 T
cells, CD8
 
1
 
 T cells, CD19
 
1
 
 B lymphocytes, and CD14
 
1
 
 
 
mono- 
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cytes using immunomagnetic beads (Dynal). The purity of the
isolated subsets was 
 
.
 
98% as determined by flow cytometry for
relevant and irrelevant subset markers (not shown).
For proliferation and BDNF production assays, 5 
 
3 
 
10
 
5
 
 freshly
isolated CD4
 
1
 
 T cells, CD8
 
1
 
 T cells, and B lymphocytes were
cultured in RPMI 1640 medium (GIBCO BRL) supplemented
with 5% FCS (GIBCO BRL) in 96-well plates (Nunc). After a
resting period of 72 h, T lymphocytes were stimulated with 5 
 
3
 
10
 
4
 
 irradiated allogeneic PBMCs and PHA (10 
 
m
 
g/ml; Sigma). B
cells were stimulated with heat-inactivated 
 
Staphylococcus aureus
 
Cowan strain 1 (SAC; Calbiochem) at a final dilution of 1:7,500.
Monocytes were stimulated in the course of purification using
anti-CD14–coated magnetic beads. Ag-specific T line cells (10
 
5
 
)
were cultured in RPMI 1640 medium supplemented with 5%
FCS plus irradiated autologous or HLA-matched PBMCs and the
relevant Ag (10–30 
 
m
 
g/ml). Proliferation was assessed by [
 
3
 
H]thy-
midine uptake. Supernatants were removed at different time
intervals after stimulation and analyzed for BDNF protein con-
centration and bioactivity. BDNF production by APCs was mea-
sured in separate wells and subtracted. The cytokine profile of
CD4
 
1
 
 T cell lines was assessed by intracellular flow cytometry
staining according to the manufacturer’s protocol (PharMingen).
 
Reverse-transcription PCR Analysis of BDNF Transcription.
 
To-
tal cellular RNA was extracted using two different RNA extrac-
tion systems (QIAGEN, and WAK Chemie). The RNA (0.5–2 
 
m
 
g)
was transcribed with random hexamer primers (Boehringer-
Mannheim) or oligo(dt) primers (GIBCO BRL), dNTP (MBI
Fermentas), and Superscript™ Reverse Transcriptase (GIBCO
BRL). All reactions were carried out in a total volume of 25 
 
m
 
l
containing 1 U 
 
Taq 
 
polymerase (QIAGEN), 200 
 
m
 
M of each
dNTP, cDNA, and 15 pmol of each primer for 35 or 40 PCR cy-
cles with annealing at 60
 
8
 
C. The correct size of the bands was de-
termined by comparison with a DNA mass standard (pUC MIX 8;
MBI Fermentas). RNA samples transcribed in the absence of
reverse transcriptase were used as negative controls to exclude
genomic contamination. All PCR products were sequenced (Me-
digene). The primer sequences were as follows: 
 
b
 
-actin forward:
5
 
9
 
-CGAGCGGGAAATCGTGCGTGA-3
 
9
 
 (position 622–642);
 
b
 
-actin reverse: 5
 
9
 
-CAGCGAGGCCAGGATGGAGCC-3
 
9
 
 (posi-
tion 1057–1037); BDNF forward: 5
 
9
 
-AGCGTGAATGGGC-
CCAAGGCA-3
 
9
 
 (position 208–228); BDNF reverse 5
 
9
 
-TGTGAC-
CGTCCCGCCCGACA-3
 
9
 
 (position 570–551).
 
Quantification of BDNF Protein Secretion.
 
BDNF protein con-
centration was determined with a sensitive sandwich ELISA. In
brief, 96-well flat-bottomed plates (Immulon 4; Dynatech) were
coated with a chicken anti–human BDNF Ab (Promega). Re-
combinant human BDNF (used as standard; Research Diagnos-
tics, Inc.) and cell supernatants (all made up in RPMI, 5% FCS
 
plus 0.05% Tween 20 [Sigma]) were used in serial dilutions.
Bound BDNF was detected by incubating the plates with a
mouse anti–human BDNF Ab (Research Diagnostics, Inc.) fol-
lowed by peroxidase-labeled goat anti–mouse IgG (Dianova).
The plates were developed using a liquid substrate system
(Sigma), and the OD was determined at 450 nm. For enhanced
detection of BDNF in biological samples, the cell supernatants
were acid-treated for 15 min before the assays. This treatment did
not change detection of the standard. Specificity of the BDNF
ELISA was established using recombinant BDNF and control
neurotrophic factors. The sensitivity of this ELISA ranges from
20 to 40 pg/ml. Quantification of BDNF was confirmed by a
second highly specific ELISA.
 
Assay for BDNF Bioactivity.
 
Biological assays were performed
using dissociated sensory neurons prepared from nodose ganglia
of 8-d-old chick embryos (14). Neurons were plated in laminin/
polyornithine-coated 48-well plastic dishes. Exogenous BDNF (1
ng/ml) and immune cell supernatants were added in the presence
or absence of the anti-BDNF mAb 4.D3.3A3, which neutralizes
the biological activity of BDNF. After 24 h, the surviving neu-
rons were counted using light microscopy. For each experiment,
duplicate wells were evaluated.
 
Immunohistochemical Analysis of Brain Sections.
 
Immunohisto-
chemistry was performed on formalin-fixed, frozen, and paraffin-
embedded human brain tissue using a mouse IgG1 mAb against
BDNF (4.FL.1A1; 10 
 
m
 
g/ml) and a polyclonal anti-BDNF anti-
serum (N-20, used at 1:500 dilution; Santa Cruz Biotechnology)
(15). Two actively demyelinating cases of multiple sclerosis, one
case of acute disseminated (postinfectious) leukoencephalitis, and
two controls without neurological disease were examined. Con-
trol sections were incubated without primary Ab or with control
IgG1 Ab. Serial sections were labeled for CD3 (1:300; Serotec),
CD68 (1:100; Dako), or human IgG (1:200; Amersham Pharma-
cia Biotech), using an avidin-biotin peroxidase method.
 
Results
 
T Cells, B Cells, and Monocytes Transcribe BDNF mRNA
and Secrete BDNF Protein.
 
BDNF was detected in CD4
 
1
 
T cells, CD8
 
1
 
 T cells, B cells, and monocytes (Fig. 1, a and
b). CD4
 
1
 
 T cells and CD8
 
1
 
 T cells were stimulated with
PHA and B cells with SAC. Monocytes were stimulated in
the course of purification with anti-CD14–coated mag-
netic beads. Fig. 1 b shows the BDNF concentrations in
supernatants of stimulated and nonstimulated cells after 72 h.
Constitutive BDNF production was observed in T cells
and B cells (white bars in Fig. 1 b). All cell types pro-
Figure 1. BDNF transcription
(a) and protein secretion (b) by
stimulated (1) and nonstimulated
(2) human immune cells. (a) RT-
PCR analysis of BDNF tran-
scripts. RNA was extracted with
RNAzol B (WAK Chemie) after
24 h of culture and reverse-tran-
scribed with oligo(dt) primers.
The middle lane represents con-
trol without reverse transcriptase
(2RT). (b) BDNF protein secre-
tion measured in supernatants after 72 h of culture. White bars (2), nonstimulated cells; black bars (1), stimulated cells (see Materials and Methods). Bars
indicate mean of duplicates; vertical lines indicate individual measurements. Lymphocyte proliferation was measured in parallel (not shown). Stimulation
indices, measured by [3H]thymidine incorporation, were .5 in all samples. B, B cells; M, monocytes. 
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duced enhanced levels of BDNF after stimulation (black
bars in Fig. 1 b). Reverse-transcription (RT)-PCR analysis
showed BDNF transcripts in T cells, B cells, and mono-
cytes (Fig. 1 a).
BDNF was also produced by Ag-specific CD4
 
1
 
 T cell
lines of different Ag specificity and cytokine profile (Table
I). Ag-induced BDNF secretion was observed both in
Th1- and in Th2-type cells (Table I).
 
Immune Cell–derived BDNF Supports Neuronal Survival In
Vitro.
 
Bioactivity of the BDNF produced by human im-
munocompetent cells was assessed by measuring the ability to
rescue cultured sensory neurons from cell death (14). CD4
 
1
 
T cells, CD8
 
1
 
 T cells, B cells, and monocytes were stimu-
lated with PHA, SAC, or anti-CD14–coated magnetic beads,
respectively. After 96 h, the supernatants were collected and
added to chicken embryonic nodose ganglia neurons to de-
termine the neuronal survival rate (Fig. 2). Neuronal survival
was supported by externally supplied recombinant BDNF
and by supernatants of activated CD4
 
1
 
 T cells, CD8
 
1
 
 T cells,
B cells, and monocytes (black bars in Fig. 2). The promotion
of neuronal survival by immune cell supernatant was due to
biologically active BDNF as demonstrated by inhibition with
anti-BDNF mAb 4.D3.3A3, which blocks the biological ac-
tivity of BDNF (white bars in Fig. 2).
 
BDNF Is Expressed by Inflammatory Cells in Acute Dis-
seminated Encephalitis and Multiple Sclerosis.
 
Strong BDNF
immunoreactivity was observed in inflammatory cells form-
ing perivascular infiltrates in cases of disseminated (postin-
fectious) leukoencephalitis and multiple sclerosis (Fig. 3).
Using serial sections, BDNF
 
1
 
 cells were found to corre-
spond to infiltrating mononuclear cells (Fig. 3). In multiple
sclerosis, BDNF
 
1
 
 lymphocytes and macrophages were not
restricted to the perivascular localization but were found
throughout the lesion (Fig. 3 g). Lesional areas with high
numbers of macrophages actively involved in demy-
elination showed enhanced BDNF immunoreactivity. In
Figure 2. Bioactivity of immune cell–derived BDNF. Chicken nodose
ganglia neurons were cultured in the presence of supernatants (diluted
1:2–1:16) of activated CD41 and CD81 T cells, B cells (B), and mono-
cytes (M). Results are shown only for the 1:2 dilution. The neuronal cell
assays were done in the presence (white bars, 1) or absence (black bars,
2) of the neutralizing anti-BDNF mAb 4.D3.3A3 (4 mg/ml). Medium
(Med) alone served as the negative control and exogenous BDNF (1 ng/
ml) as the positive control. Bars indicate mean of duplicates; vertical lines
indicate individual measurements.
 
Table I.
 
BDNF Production by Ag-specific CD4
 
1
 
 T Cell Lines
 
TCL Antigen IFN
 
1
 
IFN
 
1
 
/IL-4
 
1
 
IL-4
 
1
 
BDNF,
 
2
 
Ag BDNF,
 
1
 
Ag SI
 
% % % pg/ml pg/ml
 
CABP1 MBP 98 1 1 11 621 13
HKBP MBP 100 0 0 239
 
*
 
1,320
 
*
 
ND
TNMOG6 MOG 99 1 0 8
 
*
 
960
 
*
 
ND
CLBP3 MBP 61 8 31 220 876 172
HW
 
b
 
70 rTCR 59 12 29 0
 
*
 
370
 
*
 
ND
HWPPD PPD 24 36 40 658 1,096 131
HWTT TT 31 38 31 1,364 1,003 6
MKTT11 TT 7 9 84 0 100 5
MKB6 rPhl 3 20 77 0 356 33
MKB7 rPhl 2 14 84 0 88 687
CLBP7 MBP 2 2 96 482 1,154 471
CLBP14 MBP 0 2 98 158 920 892
CLBP16 MBP 2 4 94 62 977 393
Columns 1 and 2 list T cell line (TCL) identification code and Ag specificity (MBP, myelin basic protein; MOG, myelin oligodendrocyte glycopro-
tein; rTCR, recombinant T cell receptor 
 
b
 
 chain; TT, tetanus toxoid; PPD, purified protein derivate of 
 
Mycobacterium tuberculosis
 
; rPhl, recombinant
 
Phleum pratense
 
). Columns 3–5 indicate the cytokine profile as determined by intracellular double-staining for IFN-
 
g
 
 (IFN) and IL-4 and FACS
 
®
 
analysis (percentage of stained cells). Columns 6 and 7 show BDNF concentrations as measured by ELISA in supernatants of nonstimulated (
 
2
 
AG)
and Ag-stimulated (
 
1
 
AG) T cell lines after 72 h (*after 24 h). Column 8 lists Ag-induced stimulation measured by [3H]thymidine incorporation be-
tween 48 and 72 h (SI, stimulation index).868 Neurotrophin Production by Immune Cells
inflammatory central nervous system disease and healthy
controls, BDNF was also detected in various types of neu-
rons, ependymal cells, and weakly in astrocytes. No immu-
noreactivity was observed in oligodendrocytes or ramified
microglial cells. Similar staining patterns were observed
with the monoclonal and polyclonal Abs.
Discussion
We demonstrate that human immune cells express the
neurotrophic factor BDNF both in vitro and in inflamma-
tory brain lesions. BDNF is one of the most potent factors
supporting neuronal survival and regulating neurotransmit-
ter release and dendritic growth (2, 16, 17). Several studies
have shown that the administration of BDNF protein or the
BDNF gene can rescue injured or degenerating neurons
and induce axonal outgrowth and regeneration (6–10). Fur-
thermore, BDNF had beneficial effects in several animal
models of neurodegenerative diseases (11). Difficulties in
delivering sufficient amounts of BDNF to the site of central
nervous system lesions have so far hampered the successful
application of BDNF for treatment of human diseases (12).
Figure 3. Expression of BDNF
in inflammatory cells in acute dis-
seminated (postinfectious) leu-
koencephalitis and multiple scle-
rosis. (a, c–e) Serial sections of a
perivascular inflammatory infil-
trate in postinfectious leukoen-
cephalitis (original magnification:
31,000): (a) immunolabeling of
BDNF (mAb); (c) negative con-
trol without primary Ab; (d)
CD3-labeled T cells; (e) CD681
macrophages; (b) inflammatory
cells in a cryostat section from the
same patient stained with a poly-
clonal anti-BDNF antiserum
(original magnification: 3500).
(f–h) BDNF immunoreactivity in
multiple sclerosis (original magni-
fication: 3450): (f) in inflamma-
tory cells forming a perivascular
infiltrate, and (g) in inflammatory
cells invading the plaque area; (h)
negative control.869 Kerschensteiner et al. Brief Definitive Report
One promising strategy for the delivery of neuroprotec-
tive factors relies on retroviral transduction of neurotrophic
factors into T cell lines specific for Ag expressed in the ner-
vous system (18). Our present results indicate that this ex-
perimental strategy has a natural counterpart: T cells and
other immune cells homing to degenerative, infectious, or
autoimmune lesions express a potent neurotrophic factor,
BDNF, that may help to minimize neuronal damage. Con-
sistent with this hypothesis, it has recently been demon-
strated that the implantation of activated macrophages into
experimental spinal cord lesions leads to partial functional
recovery of paraplegic rats (19). In addition to its neu-
rotrophic effect, locally produced BDNF could have an
immunomodulatory function, e.g., by indirectly downreg-
ulating MHC class II expression on microglia (20).
NT-mediated effects on immune cells have previously
been demonstrated for nerve growth factor (21). Thus far,
however, we found no evidence that BDNF acts on pe-
ripheral human immune cells. This could be explained by
the fact that immune cells express only the truncated form
of the trkB BDNF receptor (our unpublished observations;
consistent with previous reports that the expression of the
full-length, signal-transducing form gp145trkB is restricted
to neuronal cells, whereas the truncated gp95trkB form is
widely expressed in nonneuronal tissues [5]). Further, we
did not detect significant effects of BDNF on the prolifera-
tion, cytokine production, or apoptosis of human lympho-
cytes (our unpublished data). Clearly, these negative obser-
vations by no means rule out that BDNF has a role in the
immune system, and the question of whether BDNF can
affect elements of the immune system deserves more de-
tailed study.
BDNF production by immune cells provides a novel ex-
ample of the bidirectional interaction between the nervous
system and the immune system (22, 23). It is noteworthy
that upon stimulation with Ag a large proportion of im-
mune cells, including CD41 T cell lines specific for brain
autoantigens, produce BDNF. Thus, in some circum-
stances, the immune infiltrates commonly found in inflam-
matory, ischemic, degenerative, and traumatic lesions of
the nervous system may have a protective rather than de-
structive role. This could help to explain the presence of
large numbers of autoreactive T lymphocytes in the healthy
immune repertoire, a phenomenon invoked by Cohen’s
concept of the “immune homunculus” (24).
In conclusion, our demonstration that activated T cells,
B cells, and monocytes produce BDNF in vitro and in in-
flammatory lesions raises the intriguing possibility that neu-
roinflammatory reactions have a neuroprotective (side) ef-
fect. This has obvious therapeutic implications for multiple
sclerosis and other inflammatory diseases of the nervous
system (25). Production of both neurotoxic and neuropro-
tective factors emphasizes the complex role of immune
cells in inflammatory, degenerative, and regenerative pro-
cesses of the nervous system.
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